Secondary Outcomes
REMISSION
Participants in the esketamine-treated group had higher remission rates than the midazolam control group at 4 hours (10 participants [66.7%] vs 3 participants [20.0%]; Mean reduction in MADRS score from baseline to 2 weeks among participants treated with esketamine was significantly greater than among those treated with midazolam (mean [SD] reduction, 15.7 [1.5] vs 3.1 [1.3]; 